Clostridioides Difficile Infection (CDI) Market Outlook

Thelansis’s “Clostridioides Difficile Infection (CDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Clostridioides Difficile Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Clostridioides Difficile Infection (CDI) Overview

Clostridioides difficile infection (CDI) is a leading cause of healthcare-associated diarrhoea, caused by toxigenic strains of the anaerobic spore-forming bacterium Clostridioides difficile, producing toxins A and B that disrupt colonocyte tight junctions, trigger inflammatory cytokine cascades, and cause colonic epithelial necrosis. Antibiotic-induced gut microbiome disruption is the predominant predisposing factor, alongside advanced age, proton pump inhibitor use, immunosuppression, and prolonged hospitalisation. Patients present with watery diarrhoea, abdominal cramping, and fever, with severe disease manifesting as pseudomembranous colitis, toxic megacolon, and septic shock. Diagnosis relies on stool toxin PCR or enzyme immunoassay in symptomatic patients, with CT imaging assessing disease severity and complications. Fidaxomicin is the preferred first-line antibiotic given superior sustained cure rates and reduced recurrence compared to vancomycin, which remains an acceptable alternative; metronidazole is reserved for non-severe disease in resource-limited settings. Bezlotoxumab, a monoclonal antibody targeting toxin B, reduces recurrence risk in high-risk patients when administered alongside antibiotic therapy. Faecal microbiota transplantation has demonstrated compelling efficacy in recurrent CDI, with microbiota-based live biotherapeutic products, including fecal microbiota spores now approved as standardised alternatives. Prognosis is generally favourable with prompt treatment; antibiotic stewardship, contact precautions, environmental spore decontamination, and judicious antibiotic prescribing are indispensable to preventing transmission and recurrence.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)